These include relapsed and de novo T-cell acute lymphoblastic leukemia (T-ALL; RPL5, RPL22, and RPL10, respectively); gastric, endometrial and colorectal cancer (RPL22); multiple myeloma, melanoma, glioblastoma and breast cancer (RPL5) and others. This evidence concerns the gene RPL22 and plasma cell myeloma.